Clinical Trials - Washington

• A5345, Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause

  Study Location: Washington

  Eligibility: HIV-infected men and women ≥18 to ≤70 years of age, maintained on suppressive ART for a minimum of 2 years with CD4+ count...

  Enrollment: Open

  Read More

• A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term Antiretroviral Therapy A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

  Study Location: Washington

  Eligibility:

  Enrollment: Closed

  Read More

• A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection . . . Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

  Study Location: Washington

  Eligibility: Men and women who: Are at least 18 years old Have had certain lab tests done that confirm very early HIV infection Are...

  Enrollment: Open

  Read More

• A5128: Consent for Use of Stored Patient Specimens for Future Testing

  Study Location: BaltimoreWashington

  Eligibility: Genders Eligible for Study:   Both Accepts Healthy Volunteers:   Yes Sampling Method:   Non-Probability Sample...

  Enrollment: Open

  Read More

• A5346: Sitagliptin for Reducing Inflammation and Immune Activation

  Study Location: Washington

  Eligibility: Ages Eligible for Study:   18 Years and older Genders Eligible for Study:   Both Accepts Healthy Volunteers:  ...

  Enrollment: Closed

  Read More

• A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

  Study Location: Washington

  Eligibility: HIV-infected men and woman, at least 18 years of age Taking anti-HIV medications that have controlled the HIV viral load...

  Enrollment: Open

  Read More

• A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

  Study Location: BaltimoreIndiaWashington

  Eligibility: HIV infected men and women between the ages of 40 and 75 On HIV medications for at least 6 months CD4 cell count greater...

  Enrollment: Open

  Read More

• A5308: A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers

  Study Location: Washington

  Eligibility: Enrollment is closed.

  Enrollment: Closed

  Read More

• A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

  Study Location: BaltimoreWashington

  Eligibility: Men and women > 18 years, HIV+ and currently on stable antiretroviral (ARV) medications or on for at least 8 weeks and be...

  Enrollment: Closed

  Read More

• A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

  Study Location: BaltimoreWashington

  Eligibility: Men and women > 18 years old who have HIV-associated neurocognitive disorder (HAND) as defined by the Frascati...

  Enrollment: Open

  Read More

• A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

  Study Location: BaltimoreWashington

  Eligibility: Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation...

  Enrollment: Closed

  Read More